Biopharma deal value through the first half (H1) of 2026 totaled $170.11 billion, the highest H1 total in BioWorld’s records by a wide margin and a 22% increase from H1 2025’s $139.35 billion, the previous record high. Both quarters were strong, with the first quarter (Q1) contributing $79.71 billion and Q2 jumping to $90.4 billion, the highest single quarter on record after edging past Q4 2024’s $80.65 billion.
Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Tianjin Hengrui Medicine Co. Ltd. have disclosed new fibroblast activation protein-α (FAPα) inhibitors covalently linked to radiolabeled chelating agents through a linker potentially useful for the treatment of cancer, inflammatory, cardiovascular disorders and more.
Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have divulged new antibody-drug conjugates comprising antibodies targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5; CEA; CD66e) covalently linked to a cytotoxic drug potentially useful for the treatment of colorectal cancer.
The U.S. FDA declined to approve, for a third time, an investigational liver cancer drug regimen comprising HLB Co. Ltd.’s rivoceranib and Jiangsu Hengrui Pharmaceutical Co. Ltd.’s camrelizumab, reportedly citing issues from a drug manufacturing facility inspection.
The U.S. FDA declined to approve, for a third time, an investigational liver cancer drug regimen comprising HLB Co. Ltd.’s rivoceranib and Jiangsu Hengrui Pharmaceutical Co. Ltd.’s camrelizumab, reportedly citing issues from a drug manufacturing facility inspection.
Biopharma deal value through the first five months of 2026 reached $135.36 billion, outpacing every prior year and topping 2025’s previous high of $103.92 billion. May was the year’s biggest month so far at $41.78 billion in transactions, making it one of the strongest individual months on record, and far outpacing April’s $13.87 billion.
A patent from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. has divulged new antibody-drug conjugates comprising antibodies covalently linked to N-myristoyltransferase 1 (NMT1) inhibitors for potential use in the treatment of cancer.
Biopharma deal value through the first five months of 2026 reached $135.36 billion, outpacing every prior year and topping 2025’s previous high of $103.92 billion. May was the year’s biggest month so far at $41.78 billion in transactions, making it one of the strongest individual months on record, and far outpacing April’s $13.87 billion. May 2026 comes in third in recent years in terms of deal value, after October 2023’s $44.91 billion and December 2022’s $42.45 billion.
Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have identified new BCL6 degradation inducers potentially useful for the treatment of autoimmune disease and cancer.
